StockData

Nektar Therapeutics vs Xilio Therapeutics

NKTR and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NKTR and XLO compare

Nektar Therapeutics is the larger company, worth 28 times as much as Xilio Therapeutics ($1.2B against $43.6M).

Xilio Therapeutics grew revenue faster over the last twelve months (327% versus −43.9% for Nektar Therapeutics).

Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −34.1% compared with −297% at Nektar Therapeutics.

Xilio Therapeutics scores higher on the StockData Score (11 against 9 for Nektar Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNKTRXLO
Size and price
Market cap$1.2B$43.6M
Share price$35.91$7.54
Change, 1 year−36.6%−23.8%
Change, 5 years−78.6%−97.3%
Beta (5Y)0.650.03
Employees6376
StockData Score
Total score911 (better)
Valuation score13 (better)
Growth score11
Performance score22
Health score55
Dividend score00
Valuation
P/S22.2×0.7× (better)
P/B1.4×0.6× (better)
FCF yield−17.0% (better)−141%
Fair value–$37.97
Margin of safety–80.1%
Growth
Revenue growth (TTM)−43.9%327% (better)
Revenue growth, 5Y average−18.4%–
Profitability
Gross margin100%–
Operating margin−254%−48.9% (better)
Net margin−297%−34.1% (better)
FCF margin−378%−95.6% (better)
Return on equity−37.3% (better)−55.0%
Return on invested capital−1186%–
Financial health
Debt / equity0.000.00
Current ratio10.42 (better)4.25
Altman Z-score−0.72 (better)−3.02
Piotroski F-score35 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions105%58.9%
Held by insiders0.46%–
Insider net buying, 12 months−$2.2M$38.3K (better)
Short interest, % of float19.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.